FINWIRES · TerminalLIVE
FINWIRES

Integral Diagnostics Says Fiscal 2026 Revenue, Net Profit After Tax Expected to Jump

By

Integral Diagnostics (ASX:IDX) said its preliminary and unaudited revenue for fiscal 2026 is expected to be around AU$788 million to AU$790 million, up around 25% year-over-year from AU$628 million in the year prior, while its operating net profit after tax is expected to be around AU$47 million to $48 million, up around 50% over the same period from AU$31.6 million, according to a Monday Australian bourse filing.

Its operating earnings before interest, taxes, depreciation, and amortization (EBITDA) is expected to be around AU$164 million to AU$165 million, up around 30% from the AU$126.5 million it reported in the previous corresponding period. Its operating EBITDA margin is expected to be around 20.8% to 21%, up around 80 basis points year-over-year.

Its diluted operating earnings are expected to be around AU$0.125 per share to AU$0.127 per share, around 23% year-over-year from AU$0.102 per share.

It also appointed Jenny Martin as its Chief Financial Officer, effective Oct. 5. Martin will join the firm as incoming CFO on Monday.

Its shares fell 1% in recent trading on Monday.

Related Articles

Asia

Aspial Lifestyle's H1 Attributable Profit Surges 88%

Aspial Lifestyle's (SGX:5UF) recorded an 88% rise in attributable profit in the first half of 2026 to SG$52.4 million from SG$27.9 million a year prior.Earnings per share stood at SG$0.0277, up from SG$0.015 previously, according to a Friday filing with the Singapore bourse.Revenue jumped 26% to SG$464.2 million from SG$367.2 million in the year-ago period.

SGX:5UF
Asia

Sino Biopharma Unit Gets China Nod to Market Lung Cancer Drug

Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group's Benmelstobart Injection obtained marketing approval from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The approval is for use of the drug in combination with chemotherapy and sequentially followed by Anlotinib Hydrochloride Capsules for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.

HKG:1177
Asia

Lygend Resources Gets CSRC Nod for China Listed-Share IPO

Lygend Resources & Technology (HKG:2245) obtained approval for its registration application related to its China listed-share initial public offering from the China Securities Regulatory Commission (CSRC).The share offering is subject to various conditions, including certain final regulatory approvals, according to a Friday Hong Kong bourse filing.

HKG:2245